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Background: Early diagnosis of patients with upper gastrointestinal cancer is important because many cases
are diagnosed in advanced stages and have poor prognosis. Several studies have reported increased serum
levels of hyaluronic acid and laminin in various cancers and the correlation of the levels with poor prognosis.
However, little data on the use of serum hyaluronic acid and laminin levels for early detection of esophageal
and gastric cancers are available.
Methods: We assessed serum hyaluronic acid and laminin levels using enzyme-linked immunosorbent assay
in 20 gastric cardia cancer, 23 gastric noncardia cancer and 20 esophageal squamous cell carcinoma incident
cases and 25 controls in the Golestan Province, northern Iran, a high risk area for upper gastrointestinal
cancers.
Results:Mean serum hyaluronic acid and laminin concentrations in cancer cases were higher than in controls
in crude analyses. Signiﬁcant correlations were observed between hyaluronic acid levels and gastric
noncardia cancer (Beta-coefﬁcient=0.390; P=0.01) and esophageal squamous cell carcinoma (Beta-
coefﬁcient=0.332; P=0.05) and between laminin levels and gastric cardia cancer (Beta-coefﬁcient=0.454;
P=0.003) in multivariate models. For esophageal squamous cell carcinoma, gastric cardia cancer, and gastric
noncardia cancer, area under ROC curve (AUC) of hyaluronic acid was 0.708, 0.694, and 0.770, and of laminin
was 0.706, 0.828, and 0.671.
Conclusions: Our study suggests that hyaluronic acid and laminin may be used to identify potentially high-risk
groups of upper gastrointestinal cancers for further diagnostic work-ups, particularly in high incidence areas.
Nevertheless, further studies with larger sample size and tumor staging information are warranted to clarify
the clinical signiﬁcance of hyaluronic acid and laminin in those cancers.
© 2011 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.1. Introduction
Hyaluronic acid and laminin are among non-collagenous compo-
nents of the extracellular matrix. Hyaluronic acid is distributed in the
extracellular space and involved in several cell functions, including cell
adhesion, migration, and proliferation [1]. Laminin is a major compo-
nent of the basement membrane and involved in several activities,se Research Centers of Tehran
of Medical Sciences.
mistry and Biophysics, Babol
abol, Iran. Tel./fax: +98 111
).
ration of Internal Medicine. Publishincluding cell adhesion, migration, differentiation and growth [2].
Several studies have reported an increase in hyaluronic acid levels in
serum, saliva, urine, or tumor tissue of patients with a verity of
malignant tumors, including multiple myeloma, mesothelioma,
and cancers of the stomach, colon, lung, breast, head and neck, and
genitourinary tract [3–13]. Elevated serum levels of laminin have also
been reported in various cancers, including cancer of the stomach,
colorectum, ovary, and hepatocellular carcinoma [2].
Gastric cancer is the second most common cause of mortality from
cancer in theworld [14]. A few tumormarkers suchas carcinoembryonic
antigen and alpha-fetoprotein are reported useful to predict the
prognosis of gastric cancer, but these serologic markers are most often
elevated in patients with end-stage disease and are not useful for early
detection [15]. Esophageal cancer is the sixth most common cause ofed by Elsevier B.V. All rights reserved.
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esophageal adenocarcinoma is increasing in several industrialized
countries, [16,17] themainhistological subtypeof the cancerworldwide
is esophageal squamous cell carcinoma [14]. The majority of the
esophageal squamous cell carcinoma patients is diagnosed with
advanced metastatic cancer and have poor prognosis [18]. Early
diagnosis may considerably increase the survival of the patients with
gastric cancer or esophageal squamous cell carcinoma [19,20]. The
standard method to diagnose these cancers is examination of tissue
specimens obtained during upper gastrointestinal (UGI) endoscopy.
Identiﬁcation of reliable, less-invasive serum markers for detection of
early-stage gastric cancer and esophageal squamous cell carcinomamay
be helpful in improvement of the prognosis [19].
Themajority of previous studies on the association of hyaluronic acid
and laminin with cancer investigated the predictive value of those
biomarkers amongknown cancer cases,whichgenerally showedpoorer
prognosis with elevated biomarker levels. Very few studies have
examined the efﬁciency of hyaluronic acid and laminin as diagnostic
tumor markers, with both positive [6,8,13] and negative results [21]. So
far, little data on the use of serum hyaluronic acid and laminin levels for
early detection of esophageal and gastric cancers are available. To
address this issue, we assessed serum concentrations of hyaluronic acid
and laminin in patients with esophageal squamous cell carcinoma or
gastric adenocarcinoma and in individuals without cancer in Golestan
Province, a high incidence area for esophageal squamous cell carcinoma
in northern Iran [22]. Gastric cancer, including cardia adenocarcinoma,
is also a common malignancy in Golestan [23].
2. Materials and methods
2.1. Study participants
Cases and controls were individuals with UGI symptoms who were
referred to Atrak clinic, the only specialized clinic for UGI cancer in
eastern Golestan, from February 2008 to September 2009 and agreed to
participate in the study. All of the referred individuals underwent upper
esophagogastroduodenoscopy at the clinic. Details of the diagnostic
procedures are presented elsewhere [23]. Eligible case subjects were
those who received diagnosis of an UGI cancer at the clinic in the
speciﬁed time period. We selected the controls from those with normal
endoscopy among the outpatients, who were referred to our clinic
because of their benign UGI disorders. Eligible participants with a
history of cancer, gastrointestinal bleeding, chronic liver disease, and
any chronic inﬂammatory diseases (such as rheumatoid arthritis) were
excluded. Finally, 20 patients with gastric cardia cancer, 23 with gastric
noncardia cancer, 20 with esophageal squamous cell carcinoma, and 25
controls were enrolled in the study.
Data on demographic characteristics and habits, including tobacco
and opium use were collected using structured questionnaires, which
were administered by trained interviewers in face-to-face interviews.
Ever opium use and ever cigarette smoking were deﬁned as using
opium at least once per week and smoking cigarette at least once per
day for duration of at least 6 months.
One day before blood sampling, all cases and controls underwent
upper esophagogastroduodenoscopy at the clinic. After that, fasting
blood samples (5 ml) were obtained from all participants. Within 2 h
following sample collection, the blood samples were centrifuged (at
2500 g for 5 min) and serum samples were stored in−20 °C freezers.
Written, informed consent was obtained from all participants. The
study was reviewed and approved by the Ethics Committee of
Golestan University of Medical Sciences.
2.2. Hyaluronic acid assay
Hyaluronic acid levels were measured with enzyme-linked immu-
nosorbent assay (ELISA), using hyaluronic acid-ELISA kits (hyaluronicacid-test, product number: K-1200, Echelon Bioscience Inc, USA) and an
ELISA reader (Immunoscan, Lab System, Switzerland). The hyaluronic
acid-ELISA is a competitive ELISA assay inwhich colorimetric signals are
inversely proportional to the amount of hyaluronic acid present in the
sample. Samples were ﬁrst mixed with the detector, and then added to
the hyaluronic acid ELISA plate for competitive binding. An enzyme-
linked antibody and colorimetric detection was used to identify the
hyaluronic acid detector bound to the plate. The concentration of
hyaluronic acid in samples was determined by a standard curve using
the reagent blank (0 ng hyaluronic acid/ml) and hyaluronic acid
reference solutions (50, 100, 200, 400, 800 and 1600 ng hyaluronic
acid/ml). Serumhyaluronic acid concentrationswere determined in the
sameanalytical batch in oneworkingday. The coefﬁcient of variation for
intra-assay variability of the procedure was 5%.
2.3. Laminin assay
Serum laminin levels were measured with enzyme-linked immu-
nosorbent assay, using laminin EIA kits (Takara Bio, code number:
MK107) and an ELISA reader (Immunoscan, Lab System, Switzerland).
The laminin-EIA kit is a solid phase EIA based on a sandwich method
that utilizes two mouse monoclonal anti-laminin antibodies to detect
laminin by a two-step procedure. One of the antibodies is bound to a
microplate to create the solid phase. Non-speciﬁc binding is blocked
by a blocking buffer. Samples and standards were incubated in
microplate wells. After washing the plate, the second anti-laminin
that was labeled with peroxidase (POD) was added to the wells and
incubated. During these steps, laminin was captured onto the solid
support on one side and tagged on the other by POD-anti-laminin. The
reaction between POD and substrate (H2O2 and tetramethybenzi-
dine) resulted in color development with intensities proportional to
the amount of laminin present in the samples and standards. The
amount of laminin was determined by measuring the absorbance's
using an EIA plate reader. Accurate sample concentrations of laminin
were determined by comparing their speciﬁc absorbance with those
obtained for the standards plotted on a standard curve. A standard
curve using 5, 10, 20, 40, 80, 160 and 320 ng/ml laminin was used to
convert sample absorbance's into ng/ml of laminin. The coefﬁcients of
variation for intra-assay and inter-assay variability of the procedure
were 4.0–5.7% and 0.3–5.0%. Again, serum laminin concentrations
were determined in the same analytical batch in one working day.
2.4. Statistical analysis
Mean and standard deviation of age and frequency distribution of
demographic characteristics, ever-cigarette smoking, ever-opium use,
and history of cancer in familywere reported for controls and caseswith
esophageal squamous cell carcinoma, gastric cardia cancer, and gastric
noncardia cancer. The values for each cancer groupwere comparedwith
of controls, using Student's t-test for continues and Fisher's exact test for
categorical variables. The normality of the distribution of hyaluronic
acid and laminin values for all participants and among controls was
assessed by Q–Q plots and the Shapiro–Wilk W test. The distributions
were found tobe severely skewed; thusweused log-transformedvalues
of hyaluronic acid and laminin. Distribution of laminin values was
skewed even after log transformation. When 3 outliers for log-
transformed laminin (1 from control and 2 from gastric cardia cancer
groups) were not considered, normality was attained. Therefore, we
excluded those 3 outlier values for geometric mean calculations and in
regression models. We conducted linear regression models and
reported Beta-coefﬁcients and P values for relationship of hyaluronic
acid and laminin, as dependent variables, with cancer status both in
crude analyses and in multivariate models in which age, sex, ethnicity
and ever-cigarette smoking were also included.
The diagnostic accuracy of the serum hyaluronic acid and laminin
was evaluated using receiver operating characteristic (ROC) curve
Table 1










Mean (SD), years 58.1 (10.2) 65.5 (13.0) 65.5 (11.2) 65.4 (10.0)
P valueb – 0.038 0.027 0.016
Sex
Women/men 14 (56%)/11 (44%) 8 (40%)/12 (60%) 4 (20%)/16 (80%) 7 (30%)/16 (70%)
P valuec – 0.37 0.018 0.09
Place of residence
Rural/urban 24 (96%)/1 (4%) 16 (80%)/4 (20%) 17 (85%)/3 (15%) 20 (87%)/3 (13%)
P valuec – 0.16 0.31 0.34
Ethnicity
Turkmen/non-Turkmen 22 (88%)/3 (12%) 13 (72%)/5 (28%) 15 (75%)/5 (25%) 11 (48%)/12 (52%)
P valuec – 0.25 0.44 0.004
Formal education
No/yes 17 (74%)/6 (26%) 16 (84%)/3 (16%) 17 (89%)/2 (11%) 22 (96%)/1 (4%)
P valuec – 0.48 0.26 0.10
Cigarette smoking
Ever/never 24 (96%)/1 (4%) 12 (63%)/7 (37%) 18 (90%)/2 (10%) 19 (83%)/4 (17%)
P valuec – 0.014 0.58 0.18
Opium use
Ever/never 23 (100%)/0 (0%) 11 (61%)/7 (39%) 15 (75%)/5 (25%) 16 (70%)/7 (30%)
P valuec – 0.001 0.016 0.009
Cancer in family
No/yes 22 (92%)/2 (8%) 10 (56%)/8 (44%) 14 (70%)/6 (30%) 18 (78%)/5 (22%)
P valuec – 0.010 0.12 0.25
Abbreviations: ESCC, esophageal squamous cell carcinoma; GCA, gastric cardia cancer; GNCA, gastric noncardia cancer.
a As a result of missing data, the sum of individuals in subgroups may be less than the total number of participants in those subgroups.
b P values for the difference between cancer and control groups were calculated using Student's t-tests.
c P values for the difference between cancer and control groups were calculated using Fisher's exact tests.
60 K. Aghcheli et al. / European Journal of Internal Medicine 23 (2012) 58–64analysis, which correlates true- and false-positive rates (sensitivity
and 1-speciﬁcity). As we used non-parametric ROC analyses, the
original values of hyaluronic acid and laminin (rather than log-
transformed values) were included in the analyses. The area under the
ROC curves (AUC) and the corresponding 95% conﬁdence intervals
(CI) were also calculated. An AUC of 1.0 is characteristic of an ideal
test, whereas 0.5 indicates a test of no diagnostic value [24]. Taking
sensitivity and speciﬁcity into account, the optimal cutoff points were
selected according to maximum values of sensitivity plus speciﬁcity.
Accuracy, sensitivity, speciﬁcity, positive predictive value (PPV) and
negative predictive value (NPV) were calculated using 2×2 tables. AllTable 2
Beta-coefﬁcients (P values) for relationship of HA and LN with age, sex, ethnicity, cigarette
Variables Control ESCC GCA
HA LN HA LN HA
Age
Crude 0.342 (0.09) 0.329 (0.12) 0.043 (0.86) 0.450 (0.05) −0.003 (0.9
Adjusted 0.267 (0.23) 0.255 (0.24) 0.258 (0.43) 0.513 (0.12) 0.037 (0.8
Sex
Crude 0.046 (0.83) −0.253 (0.23) 0.237 (0.31) 0.018 (0.94) 0.455 (0.0
Adjusted −0.030 (0.89) −0.323 (0.16) 0.163 (0.56) 0.139 (0.60) 0.363 (0.1
Ethnicity
Crude −0.085 (0.67) 0.322 (0.13) −0.544 (0.02) 0.213 (0.40) 0.277 (0.2
Adjusted −0.112 (0.60) 0.258 (0.24) −0.604 (0.06) 0.222 (0.43) 0.288 (0.3
Cigarette smoking
Crude 0.319 (0.12) 0.132 (0.54) 0.126 (0.61) 0.357 (0.13) 0.191 (0.4
Adjusted 0.297 (0.19) 0.220 (0.33) −0.167 (0.58) 0.052 (0.86) 0.012 (0.9
Opium use
Crude – – −0.018 (0.94) −0.005 (0.98) 0.215 (0.3
Adjusted – – 0.119 (0.67) 0.150 (0.58) 0.308 (0.3
Cancer in family
Crude 0.099 (0.65) 0.303 (0.16) 0.040 (0.87) −0.635 (0.01) −0.119 (0.6
Adjusted −0.232 (0.46) 0.412 (0.17) −0.445 (0.34) −0.571 (0.19) −0.009 (0.9
Abbreviations: ESCC, esophageal squamous cell carcinoma; GCA, gastric cardia adenocarcin
a Variables were as follows: age (continuous variable in years), sex (men vs. women) ethn
vs. never), and cancer in family (yes vs. no). Beta coefﬁcients and P values were driven from li
other variables in the table were included.statistical analyses were performed using STATA software, version
11.0. Throughout of this article, two-sided P valuesb0.05 are con-
sidered as statistically signiﬁcant.
3. Results
Demographic characteristics of study participants are shown in
Table 1. Cancer cases in average were older than controls; the
approximate mean age was 58 years for controls and 65 years for
cancer cases. While slightly more women than men were enrolled as
controls, the number of men was higher in cancer groups. The majorityand opium use, and history of cancer in family by cancer status a.
GNCA All participants
LN HA LN HA LN
9) 0.311 (0.21) 0.376 (0.08) −0.073 (0.74) 0.299 (0.005) 0.310 (0.004)
9) 0.165 (0.61) 0.530 (0.04) −0.047 (0.86) 0.239 (0.033) 0.292 (0.015)
4) 0.068 (0.79) 0.252 (0.25) 0.074 (0.74) 0.271 (0.011) 0.066 (0.55)
8) 0.094 (0.77) 0.363 (0.14) 0.200 (0.44) 0.213 (0.058) 0.034 (0.78)
4) −0.387 (0.11) −0.033 (0.88) 0.156 (0.48) 0.061 (0.58) 0.154 (0.17)
1) −0.401 (0.25) −0.325 (0.20) 0.062 (0.82) 0.031 (0.76) 0.111 (0.37)
2) 0.173 (0.49) 0.033 (0.88) −0.347 (0.11) 0.202 (0.06) 0.077 (0.49)
7) 0.292 (0.43) −0.190 (0.46) −0.364 (0.20) 0.046 (0.70) −0.029 (0.82)
6) 0.000 (1.00) 0.101 (0.65) −0.132 (0.55) 0.205 (0.06) 0.053 (0.64)
0) −0.307 (0.39) −0.077 (0.76) −0.050 (0.86) 0.129 (0.27) 0.036 (0.77)
2) 0.347 (0.16) −0.159 (0.47) −0.319 (0.14) 0.063 (0.57) −0.030 (0.79)
8) 0.128 (0.73) −0.057 (0.83) −0.317 (0.25) 0.079 (0.48) 0.018 (0.88)
oma; GCNA, gastric noncardia adenocarcinoma; HA, hyaluronic acid; LN, laminin.
icity (non-Turkmen vs. Turkmen), cigarette smoking (ever vs. never), opium use (ever
near regressionmodels. Adjusted values were driven frommultivariate models in which
Table 3










Control 72.2 (49.7–104.8) Reference – Reference –
ESCC 135.6 (105.3–175.0) 0.387 0.009 0.332 0.049
GCA 136.0 (103.1–179.2) 0.381 0.010 0.249 0.12
GNCA 162.4 (125.2–210.8) 0.471 0.001 0.390 0.011
Laminin d
Control 59.2 (54.6–64.3) Reference – Reference –
ESCC 68.2 (63.0–73.8) 0.363 0.015 0.151 0.34
GCA 73.8 (68.4–79.6) 0.530 b0.001 0.454 0.003
GNCA 66.5 (60.3–73.3) 0.270 0.066 0.208 0.24
Abbreviations: B.coeff, Beta-coefﬁcient; CI, conﬁdence interval; ESCC, esophageal
squamous cell carcinoma; GCA, gastric cardia adenocarcinoma; GCNA, gastric
noncardia adenocarcinoma; HA, hyaluronic acid; LN, laminin.
a Levels of HA and LN are presented as ng/ml.
b Beta-coefﬁcients and P values were calculated using linear regression models.
c Adjusted Beta-coefﬁcients and P values are driven from multiple linear regression
models in which age, sex, ethnicity, and ever-smoking were also included.
d All values calculated after exclusion of 2 outliers from GCA and 1 outlier from
control groups.
61K. Aghcheli et al. / European Journal of Internal Medicine 23 (2012) 58–64of cases and controls resided in rural areas and did not have formal
education. More esophageal squamous cell carcinoma cancer than
controls had ever-smoked cigarette (P=0.001). Opium use was more
common among cancer cases than controls; none of controls had ever
used opium. History of cancer in family was also more common among
esophageal squamous cell carcinoma cases than in controls (P=0.01).
Distribution of hyaluronic acid and laminin levels in serum by
disease status is shown in the Supplementarymaterial. Beta-coefﬁcients
and P values for relationship of hyaluronic acid and laminin with age,
sex, ethnicity, cigarette andopiumuse, andhistoryof cancer in family by
cancer status are shown in Table 2. Among controls, both age and
cigarette smoking were associated with hyaluronic acid and laminin
levels, while sex (men vs. women) was inversely associated with
laminin levels. However, none of the association was statistically
signiﬁcant. When all participants were combined, age was signiﬁcantly
associated with hyaluronic acid (Beta-coefﬁcient for one year increase
in age=0.239; P=0.03) and laminin (Beta-coefﬁcient=0.292;
P=0.02). The associations with cigarette smoking were disappeared
after adjustment for other factors, including age. There were sporadic
associations among cases that were not observed among controls, suchTable 4
ROC analysis of HA and LN levels for differentiating cancer cases from controlsa. Sensitivity





































Abbreviations: AUC, area under the ROC curves; ESCC, esophageal squamous cell carcinom
hyaluronic acid; LN, laminin; PPV, Positive predictive value; NPV, negative predictive value
a Sensitivity, speciﬁcity, positive and negative predictive values, and accuracy for each mas the association between hyaluronic acid and ethnicity among
esophageal squamous cell carcinoma cases and between hyaluronic
acid and sex among cancer cases.
Table 3 shows geometric mean (95% CI) of hyaluronic acid and
lamininbydisease status, aswell asBeta-coefﬁcients and Pvalues for the
relationship of hyaluronic acid and laminin with cancer status in
univariate and multivariate linear regression models. In multivariate
models, hyaluronic acid was associated with gastric noncardia cancer
(Beta-coefﬁcient=0.390; P=0.01) and esophageal squamous cell
carcinoma (Beta-coefﬁcient=0.332; P=0.05) and laminin was associ-
ated with gastric cardia cancer (Beta-coefﬁcient=0.454; P=0.003).
Results of ROC curve analyses are shown in Table 4 and Figs. 1 and 2.
AUC (95% CI) for hyaluronic acid was as following: 0.708 (0.549–0.869)
with esophageal squamous cell carcinoma, 0.694 (0.537–0.851) with
gastric cardia cancer, and 0.770 (0.635–0.904) with gastric noncardia
cancer. Sensitivity of hyaluronic acid for diagnosis of esophageal
squamous cell carcinoma was 80% for cut-off point of 101 ng/ml and
75% for cut-point of 109 ng/ml; the speciﬁcity was not very different
(68% vs. 72%). Sensitivity of hyaluronic acid for diagnosis of gastric
cardia cancerwas75% for cut-off point of 82 ng/ml and65% for cut-point
of 125 ng/ml; the corresponding speciﬁcity values were 60% and 72%.
For diagnosis of gastric noncardia cancer using hyaluronic acid levels,
sensitivity of cut-off points of 81 and 105 ng/ml was 91% and 74%, the
respective speciﬁcitywere 56% and 72%.Whenwe assigned a single cut-
off point (101 ng/ml) to hyaluronic acid for discrimination of all cancer
cases combined from controls, sensitivity and speciﬁcity were 73% and
68%. AUC (95% CI) for laminin with regard to gastric cardia cancer was
0.828 (0.711–0.945). Sensitivity was 90% for cut-off point of 62 ng/ml
and 80% for cut-off point of 67 ng/ml; the respective speciﬁcitywas 60%
and 68%. Sensitivity and speciﬁcity of laminin for discrimination of
esophageal squamous cell carcinoma and gastric noncardia cancerwere
lower, particularly for gastric noncardia cancer. Sensitivity and
speciﬁcity of laminin using a single cut-off point (62.1 ng/ml) for
discrimination of all cancer cases combined were 73% and 60%.
4. Discussion
This study found higher serum hyaluronic acid and laminin levels
in UGI cancer cases than in control group. Multivariate analyses
adjusted for several factors, including age, sex, ethnicity, and cigarette
smoking, conﬁrmed signiﬁcant relation of hyaluronic acid with
esophageal squamous cell carcinoma and gastric noncardia cancer









0.0 68.0 66.7 81.0 73.3
5.0 72.0 68.2 78.3 73.3
5.0 60.0 60.0 75.0 66.7
5.0 72.0 65.0 72.0 68.9
1.3 56.0 65.6 87.5 72.9
3.9 72.0 70.8 75.0 72.9
3.0 68.0 85.2 50.0 71.6
0.0 60.0 58.3 71.4 64.4
0.0 68.0 60.0 68.0 64.4
0.0 60.0 64.3 88.2 73.3
0.0 68.0 65.2 77.3 73.3
8.3 48.0 58.0 70.6 62.5
8.8 84.0 71.4 61.8 66.7
3.0 60.0 82.0 46.9 69.3
a; GCA, gastric cardia adenocarcinoma; GNCA, gastric noncardia adenocarcinoma; HA,
; ROC, receiver operating characteristic; 95% CI, 95% conﬁdence interval.
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Fig. 1. ROC curves of hyaluronic acid for discrimination of esophageal squamous cell
carcinoma, gastric cardia adenocarcinoma, and gastric noncardia adenocarcinoma cases
from control. a. ROC of hyaluronic acid for diagnosis of esophageal squamous cell
carcinoma. b. ROC of hyaluronic acid for discrimination of gastric cardia adenocarcinoma.
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Area under ROC curve = 0.6713
Fig. 2. ROC curves of laminin for discrimination of esophageal squamous cell carcinoma,
gastric cardia adenocarcinoma, and gastric noncardia adenocarcinoma cases from
control. a. ROC of laminin for discrimination of esophageal squamous cell carcinoma,
b. ROC of laminin for discrimination of gastric cardia adenocarcinoma. c. ROC of laminin
for discrimination of gastric noncardia adenocarcinoma.
62 K. Aghcheli et al. / European Journal of Internal Medicine 23 (2012) 58–64the above ﬁndings are spurious associations related to the inﬂuence of
other factors. Hyaluronic acid showed fairly good sensitivity and
speciﬁcity for discrimination of UGI cancer cases, particularly
esophageal squamous cell carcinoma and gastric noncardia cancer
cases, from controls. While similar ﬁndings were found with regard to
laminin and gastric cardia cancer, the efﬁcacy of laminin for discrim-
ination of esophageal squamous cell carcinoma and gastric noncardia
cancer was less promising.
Our results suggest that hyaluronic acid and laminin may be used as
tumor markers for the above UGI cancers. Nevertheless, increase inserum hyaluronic acid and laminin is not speciﬁc to those cancers. In
addition to several other cancers, increased serum hyaluronic acid has
been reported with liver disease and various inﬂammatory conditions,
including rheumatoid arthritis, psoriasis, scleroderma, andosteoarthritis
[25,26]. Elevated serum laminin is also reported not only with other
63K. Aghcheli et al. / European Journal of Internal Medicine 23 (2012) 58–64cancers but also with liver disease, including chronic hepatitis, cirrhosis,
and liver ﬁbrosis [27–29]. Although these biomarkers are not speciﬁc to
UGI cancers and diagnosis of those cancers should be conﬁrmed by
standard methods, serum hyaluronic acid and laminin levels may be
helpful to identify potentially high-risk groups for further diagnostic
work-ups or closer follow-ups; this can be an important issue in high
incidence areas of UGI cancers, such as Golestan.
Hyaluronic acid may be produced by tumor cells or as a result of
interactions between tumor and the surrounding connective tissue
[13,30]. Surgical removal of tumor has been associated with a reduction
in serumhyaluronic acid levels in a few studies that investigated such an
association [31]. Two different patterns have been suggested for
expression of hyaluronic acid in tumors arising from simple and
stratiﬁed epithelia [12]. With the ﬁrst group, such as cancers of the
breast, colon, and stomach, the expression correlates with tumor grade
and invasiveness. With poorly differentiated tumors and local or distant
invasion,more cancer cellswill behyaluronan-positiveorwill havemore
intense hyaluronan staining. On the other hand, early stage cancer
arising from stratiﬁed epithelia may have increased hyaluronan
expression compared to normal epithelium, but high-grade, aggressive
squamous cancers are associated with decrease in hyaluronan expres-
sion. It is not clear if any pattern also exists with serum hyaluronic acid
levels. The upper limit of hyaluronic acid levels in controls of our study
(95% CI: 50–105 ng/ml) was comparable with reported levels among
healthy individuals in other countries (range: 0–100 ng/ml), [3,21] but
higher than the levels in other parts of Iran (95% CI: 0–68 ng/ml) [28,31].
Higher age of our study controls may partly explain the higher levels in
our study.Our controlswere referred toour clinic becauseof their benign
UGI disorders. It is not clear whether benign inﬂammatory processes in
UGI are also associatedwith increased levels of hyaluronic acid in serum.
The exact source of increased serum laminin in patients with
malignant tumors is not clear. Tumor cellsmay release the enzymes that
can dissolve extracellular matrix, which may lead to release of laminin
into serum [32]. Furthermore, tumor cells may produce laminin and
other element of the basement membrane [33]. There are reports
showing a decrease in serum laminin following surgical excision of
tumors [34]. Serum laminin levels among controls in our study (95% CI:
55–64 ng/ml) were comparable to reported values from healthy
individuals in another area of Iran (95% CI: 26–66 ng/ml) [28].
One of the strengths of this study is recruitment of both non-
cancer individuals and incident, newly diagnosed cancer cases. To our
knowledge, this is the ﬁrst report on the pattern of serum hyaluronic
acid and laminin levels in esophageal squamous cell carcinoma and
gastric cancer by subtype (cardia and non-cardia) compared to non-
cancer individuals. Furthermore, many of previous studies on the
association of hyaluronic acid and laminin with cancers did not
consider potential confounding factors, such as age, that might have
inﬂuenced their results. We used multivariate analyses with adjust-
ments for several other factors to examine the relationship of
hyaluronic acid and laminin with cancers of interest.
Limitations of our study include the fairly small sample size and lack
of staging information for cancer cases. As hyaluronic acid and laminin
are also associatedwith aggressiveness of tumors, increased levels of the
biomarkers in our study, or a part of it,may be related topresence of local
or distant invasion by tumor rather than early-stage cancer. We did not
have information on the stage of tumors. Although it is unlikely that the
majority of cases had very advanced disease, because they were newly
diagnosed cases and generally without overt signs of distant metastasis,
the cancer cases might have referred with tumors in different stages.
Further studies with staging information are warranted to study
hyaluronic acid and laminin levels in different stages of UGI cancers.
5. Conclusions
In summary, our study found elevated levels of serum hyaluronic
acid and laminin in UGI cancers, suggesting that those biomarkersmay be used for early diagnosis purposes. Increased levels of
hyaluronic acid and laminin may also be seen in certain other cancers
and inﬂammatory disease. Nevertheless, those biomarkers may be
helpful to identify potentially high-risk groups for further diagnostic
work-ups or closer follow-ups, particularly in high incidence areas
of UGI cancers, and as it is shown in other studies to predict the
prognosis of those cancers. Further studies with larger sample size
and tumor staging information are required to clarify the clinical
signiﬁcance of serum concentration of hyaluronic acid and laminin as
tumormarkers for esophageal squamous cell carcinoma, gastric cardia
cancer, and gastric noncardia cancer.
Learning points
• Serum hyaluronic acid and laminin levels measurement in cases
with UGI cancers may be helpful to identify potentially high-risk
groups for further diagnostic work-ups.
Abbreviations
ESCC esophageal squamous cell carcinoma
GCA gastric cardia adenocarcinoma




There is no conﬂict-of-interest or ﬁnancial disclosure in the
manuscript.
Acknowledgments
We sincerely thank the staff of Atrak clinic, including Dr Haji-Amin
Marjani, Safora Kor, Bita Mohammadi, Maral Eskandar Nezhad, Ashur
Yolmeh, and also the Digestive Disease Research Centers of Tehran
University of Medical Sciences and Golestan University of Medical
Sciences for their ﬁnancial support.
Appendix A
Supplementary data to this article can be found online at doi:10.
1016/j.ejim.2011.07.018.
References
[1] Genasetti A, Vigetti D, Viola M, Karousou E, Moretto P, Rizzi M, et al. Hyaluronan
and human endothelial cell behavior. Connect Tissue Res 2008;49:120–3.
[2] Rosa H, Parise ER. Is there a place for serum laminin determination in patients with
liver disease and cancer? World J Gastroenterol 2008;14:3628–32.
[3] Cooper EH, Forbes MA. Serum hyaluronic acid levels in cancer. Br J Cancer
1988;58:668–9.
[4] Delpech B, Chevallier B, Reinhardt N, Julien JP, Duval C, Maingonnat C, et al. Serum
hyaluronan (hyaluronic acid) in breast cancer patients. Int J Cancer 1990;46:
388–90.
[5] Wang C, Tammi M, Guo H, Tammi R. Hyaluronan distribution in the normal
epithelium of esophagus, stomach, and colon and their cancers. Am J Pathol
1996;148:1861–9.
[6] Franzmann EJ, Schroeder GL, Goodwin WJ, Weed DT, Fisher P, Lokeshwar VB.
Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head
and neck tumors. Int J Cancer 2003;106:438–45.
[7] Vizoso FJ, del Casar JM, Corte MD, Garcia I, Corte MG, Alvarez A, et al. Signiﬁcance
of cytosolic hyaluronan levels in gastric cancer. Eur J Surg Oncol 2004;30:318–24.
[8] Eissa S, Kassim SK, Labib RA, El Khouly IM, Ghaffer TM, Sadek M, et al. Detection of
bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin
20 RNAs. Cancer 2005;103:1356–62.
[9] Gotte M, Yip GW. Heparanase, hyaluronan, and CD44 in cancers: a breast
carcinoma perspective. Cancer Res 2006;66:10233–7.
[10] Gao ZL, Zhang C, Du GY, Lu ZJ. Clinical signiﬁcance of changes in tumor markers,
extracellular matrix, MMP-9 and VEGF in patients with gastric carcinoma.
Hepatogastroenterology 2007;54:1591–5.
64 K. Aghcheli et al. / European Journal of Internal Medicine 23 (2012) 58–64[11] Misra S, Hascall VC, Berger FG, Markwald RR, Ghatak S. Hyaluronan, CD44, and
cyclooxygenase-2 in colon cancer. Connect Tissue Res 2008;49:219–24.
[12] Tammi RH, Kultti A, Kosma VM, Pirinen R, Auvinen P, Tammi MI. Hyaluronan in
human tumors: pathobiological and prognostic messages from cell-associated and
stromal hyaluronan. Semin Cancer Biol 2008;18:288–95.
[13] Xing RD, Chang SM, Li JH, Li H, Han ZX. Serum hyaluronan levels in oral cancer
patients. Chin Med J (Engl) 2008;121:327–30.
[14] Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin
2005;55:74–108.
[15] Wu CW, Chi CW, Lin WC. Gastric cancer: prognostic and diagnostic advances.
Expert Rev Mol Med 2002;4:1–12.
[16] Trivers KF, Sabatino SA, Stewart SL. Trends in esophageal cancer incidence by
histology, United States, 1998–2003. Int J Cancer 2008;123:1422–8.
[17] Steevens J, Botterweck AA, Dirx MJ, van den Brandt PA, Schouten LJ. Trends in
incidence of oesophageal and stomach cancer subtypes in Europe. Eur J
Gastroenterol Hepatol 2010;22:669–78.
[18] Iyer RB, Silverman PM, Tamm EP, Dunnington JS, DuBrow RA. Diagnosis, staging,
and follow-up of esophageal cancer. AJR Am J Roentgenol 2003;181:785–93.
[19] Whiting J, Sano T, Saka M, Fukagawa T, Katai H, Sasako M. Follow-up of gastric
cancer: a review. Gastric Cancer 2006;9:74–81.
[20] Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241–52.
[21] Frebourg T, Lerebours G, Delpech B, Benhamou D, Bertrand P, Maingonnat C, et al.
Serum hyaluronate in malignant pleural mesothelioma. Cancer 1987;59:2104–7.
[22] Islami F, Kamangar F, Nasrollahzadeh D, Moller H, Boffetta P, Malekzadeh R.
Oesophageal cancer in Golestan Province, a high-incidence area in northern Iran—
a review. Eur J Cancer 2009;45:3156–65.
[23] Islami F, Kamangar F, Aghcheli K, Fahimi S, Semnani S, Taghavi N, et al.
Epidemiologic features of upper gastrointestinal tract cancers in northeastern
Iran. Br J Cancer 2004;90:1402–6.[24] Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a
fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561–77.
[25] Laurent TC, Fraser JR. Hyaluronan. FASEB J 1992;6:2397–404.
[26] Belo JN, Berger MY, Reijman M, Koes BW, Bierma-Zeinstra SM. Prognostic factors
of progression of osteoarthritis of the knee: a systematic review of observational
studies. Arthritis Rheum 2007;57:13–26.
[27] Parsian H, Nouri M, Soumi MH, Rahimipour A, Qujeq D. Attenuation of serum
laminin concentrations upon treatment of chronic hepatitis. N Z J Med Lab Sci
2009;63:12–7.
[28] Parsian H, Rahimipour A, Nouri M, Somi MH, Qujeq D, Fard MK, et al. Serum
hyaluronic acid and laminin as biomarkers in liver ﬁbrosis. J Gastrointestin Liver
Dis 2010;19:169–74.
[29] Parsian H, Rahimipour A, Nouri M, Somi MH, Qujeq D. Assessment of liver ﬁbrosis
development in chronic Hepatitis B patients by serum hyaluronic acid and laminin
levels. Acta Clin Croat 2010;49:257–65.
[30] Knudson W, Biswas C, Toole BP. Interactions between human tumor cells and
ﬁbroblasts stimulate hyaluronate synthesis. Proc Natl Acad Sci USA 1984;81:
6767–71.
[31] Kumar S,West DC, Ponting JM, Gattamaneni HR. Sera of childrenwith renal tumours
contain low-molecular-mass hyaluronic acid. Int J Cancer 1989;44:445–8.
[32] Skubitz AP, Bast Jr RC, Wayner EA, Letourneau PC, Wilke MS. Expression of alpha 6
and beta 4 integrins in serous ovarian carcinoma correlates with expression of the
basement membrane protein laminin. Am J Pathol 1996;148:1445–61.
[33] Chu Y, Yang Y, Lin M, Wang Z. Detection of laminin in serum and ascites from
patients with epithelial ovarian tumor. J Huazhong Univ Sci Technolog Med Sci
2002;22:58–9 68.
[34] Iwahashi M, Ikoma M, Otani T, Ooshima A, Nakano R. Increased serum
concentrations of type IV collagen and laminin associated with granulosa cell
tumour of the ovary. J Clin Pathol 1997;50:77–9.
